Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
Andrea Rognoni, Alessadro Lupi, Chiara Cavallino, Roberta Rosso, Alessia Veia, Sara Bacchini and Angelo Sante Bongo
Affiliation: Coronary Care Unit and Catheterization Laboratory, Hospital “Maggiore della Carita”, Corso Mazzini 18, 28100 Novara, Italy.
Keywords: STEMI, Acute coronary syndrome, adjuvant therapy, bleeding, GP IIb/IIIa inhibitors, in – stent restenosis, no –
reflow phenomenon, percutaneous coronary intervention, platelet, thrombosis.
Acute coronary syndromes and, in paticular, ST – segment elevation myocardial infarction are the principle
causes or mortality and morbidity in the industrialized countries. The manadgement of acute myocadial infarction is much
debated in the literature; primary percutaneous coronary intervention is the treatment of choice. In the recent years there
has been an increasing interest in the concept of adjunctive pharmacological therapy to improve outcomes in primary
percutaneous coronary intervention. In the literature randomized trials of intravenous or more recently intracoronary
injection of glycoprotein IIb/IIIa inhibitors have provided conflicting results with no definitive evidence for efficacy. The
aim of the report is to review the evidence to our date on the role of intracoronary injection of abciximab during primary
percutaneous intervention in the setting of acute myocardial infarction.
Rights & PermissionsPrintExport